

ASX ANNOUNCEMENT MARKET RELEASE

10 November 2022

INITIAL DIRECTOR'S INTEREST NOTICE

Perth, Western Australia - Australian medical technology company, Artrya Limited (ASX: AYA, **Artrya or the Company**) creator of the AI-based solution, Artrya Salix, that supports physicians in the diagnosis of coronary artery disease, today advises that, due to an administrative oversight, the Initial Director's Interest Notice for Dr Jacque Sokolov was not lodged with ASX on the appointment of Dr Sokolov as a director of the Company on 1 August 2022.

Attached is the Appendix 3X for Dr Sokolov.

This announcement was approved by the Artrya Managing Director and Company Secretary.

For further information please contact:

Investor Enquiries:

John Barrington

Artrya Limited

+61 419 850 502

investors@artrya.com

Media Enquiries:

Brett McCarthy

Artrya Limited

+61 401 704 451

brett.mccarthy@artrya.com

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ARTRYA LIMITED
ABN	53 624 005 741

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	JACQUE SOKOLOV
Date of appointment	1 AUGUST 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Number & class of securities</p> <p>Dr Jacque J Sokolov:</p> <p><u>Options – issued on 13 January 2022 on entry into a consultancy agreement</u></p> <ul style="list-style-type: none">• 1,300,000 unlisted options exercisable at \$1.35 per option on or before 13 January 2027• 1,300,000 unlisted options exercisable at \$3.00 per option on or before 13 January 2027• 1,300,000 unlisted options exercisable at \$5.00 per option on or before 13 January 2027

+ See chapter 19 for defined terms.

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
N/A	N/A

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.